Neurotrophic Keratitis Treatment Market Trends Analysis, Market Opportunities, Key Players, Share And Forecast To 2033

The neurotrophic keratitis treatment market size has grown strongly in recent years. It will grow from $4.7 billion in 2023 to $5.1 billion in 2024 at a compound annual growth rate (CAGR) of 8.5%. The growth in the historic period can be attributed to increased diagnoses, increasing injury and surgical procedures, rising research and development, global healthcare infrastructure.

The neurotrophic keratitis treatment market size is expected to see strong growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to educational initiatives, increasing clinical trials, advanced therapies, regulatory approvals. Major trends in the forecast period include improved diagnostic tools, digital health solutions, neuroprotection strategies, advanced ocular surface imaging.

Market Overview -
Neurotrophic keratitis treatment refers to a treatment method to cure a rare eye condition caused by damage to the trigeminal nerve, leading to decreased corneal sensation and potential corneal damage. This treatment is used to protect the cornea, promote healing, alleviate symptoms, and prevent further damage.

Download Free Sample of Report -

https://www.thebusinessresearchcompany.com/sample.aspx?id=12968&type=smp

Rising Prevalence Of Eye Diseases Fuels Growth In The Neurotrophic Keratitis Treatment Market
The growing prevalence of eye diseases is expected to propel the growth of the neurotrophic keratitis treatment market going forward. Eye diseases are a wide range of medical problems and disorders that affect the structure and function of the eyes. Neurotrophic keratitis can aid in the improvement of corneal sensation, the promotion of healing, the prevention of infection, and the relief of pain and suffering. For instance, in March 2022, according to the reports shared by Eye Care One, a US-based eyecare career development services platform, it was estimated that 35 million US people will suffer from dry eye disease (DED) in 2022 and the prevalence will rise yearly. Furthermore, in March 2021, according to the Eyes of the World Foundation, a Spain-based non-profit organization, there will be 1.1 billion people with vision loss in 2021, which is estimated to increase to 1.7 billion by 2050. Therefore, the growing prevalence of eye diseases is driving the growth of the neurotrophic keratitis treatment market.

Competitive Landscape -
Major players in the neurotrophic keratitis treatment market are Eyevance Pharmaceuticals LLC, Grand Pharma Co. Ltd., Walgreen Co., Pfizer Inc., Johnson and Johnson, Bayer AG, Novartis AG, Abbott Laboratories, Gilead Biosciences Inc., Merck and Co. Inc., Allergan Inc., Alcon Inc., Bausch Health Companies Inc., Bausch & Lomb Inc., CooperVision Inc., Rohto Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Zhejiang Conba Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Dompe farmaceutici S.p.A, Aurolab, Ocular Therapeutix Inc., Laboratoires Thea SAS, Leadiant Biosciences Inc., ReGenTree LLC, Contacare Opthalmic Private Limited, Neuroptika Inc., Surgitech Innovation Private Limited.

Innovative Drug Development Shapes The Landscape Of Neurotrophic Keratitis Treatment Market
Major companies operating in the neurotrophic keratitis treatment market are developing innovative drugs and getting them approved to uphold their market position. Drug development is vital in neurotrophic keratitis treatment as current treatments are limited and there is a need for more effective treatments to prevent the progression of the disease. For instance, in December 2022, BRIM Biotechnology Inc., a Taiwan-based clinical-stage company, received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for BRM424 for the treatment of neurotrophic keratitis (NK). It is a recombinant type of human nerve growth factor that stimulates the proliferation and differentiation of corneal limbal stem cells to regenerate and restore the cornea's health in patients with neurotrophic keratitis.

Browse Full Report @

https://www.thebusinessresearchcompany.com/report/neurotrophic-keratitis-treatment-global-market-report

Key Segments -

The neurotrophic keratitis treatment market covered in this report is segmented -

1) By Treatment: Topical Antibiotics; Recombinant Human Nerve Growth Factor (rhNGF); Amniotic Membrane Transplantation; Keratoplasty; Other Treatments
2) By Route of Administration: Oral; Topical; Other Routes of Administration
3) By Application: Stage I; Stage II; Stage III
4) By End-User: Hospitals; Homecare; Specialty Clinics; Other End-Users

Key highlights covered in the report -
1. Detailed market size forecast and historical data analysis
2. Key drivers influencing market growth
3. Identification of upcoming trends and potential opportunities in the market
4. Analysis of major players strategies, to understand competitive dynamics and market positioning
5. Evaluation of regional dynamics

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Want To Know More About The Business Research Company?

The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database

The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps

This release was published on openPR.